Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide phase 2b study in chronic kidney disease with type 2 diabetes mellitus
2020-000255-12Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change and percentage change in UACR versus placebo from baseline to the end of 14 weeks of dosing in Cohort 1. Status: unknown.
02
Drugs
cotadutide
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000255-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000255-12.